Sangamo Therapeutics Enters Research Evaluation and Option Agreement with Prevail Therapeutics

1 Mins read

Sangamo Therapeutics, a leading biotechnology company, announced on Monday a research evaluation and option agreement with Prevail Therapeutics, a subsidiary of Eli Lilly and Company.

Evaluating Proprietary Sangamo Adeno-Associated Virus Capsids

As part of the global agreement, Prevail will receive the rights to conduct in vitro and in vivo studies to evaluate specific proprietary Sangamo adeno-associated virus capsids. In return, Sangamo will receive an upfront payment.

Exclusive License for Multiple Neurological Targets

In addition to the evaluation rights, Prevail also has the option to secure an exclusive license for the use of the capsids across multiple undisclosed neurological targets.

Potential Financial Benefits for Sangamo

Should Prevail choose to exercise the option for all targets and successfully gain approval for a Prevail product utilizing the licensed capsids in both the United States and Europe, Sangamo stands to benefit significantly. This includes:

  • Up to $415 million in exercise fees and developmental milestone payments
  • Up to $775 million in commercial milestone payments
  • Tiered royalties based on net sales of Prevail products

Prevail’s Responsibility for Development and Commercialization

Under the agreement, Prevail will take the lead in all future development, manufacturing, and commercialization efforts related to the products.

Positive Market Reaction

News of the agreement has had a positive impact on Sangamo Therapeutics’ market performance. As of premarket trading on Monday, the company’s shares rose by 12% to $1.44.

Related posts

U.S. Stock Futures Rise as Inflation Gauge May Fall Below 4%

1 Mins read
U.S. stock futures are on the rise today in anticipation of new data that may reveal a decrease in an inflation gauge…

Kanabo Group Reports Narrowed Pretax Loss for First Half-Year

1 Mins read
Kanabo Group, a leading medical-cannabis company, has announced a substantial reduction in its pretax loss for the first half of the year….

Trump's Chances of Winning the 2024 Presidential Election on the Rise

1 Mins read
According to betting markets tracked by RealClearPolitics, Donald Trump’s chances of winning the 2024 presidential election have seen an improvement this week….

Leave a Reply

Your email address will not be published. Required fields are marked *

71 − 66 =